Amarin Corp Plc (AMRN)

[jessellivermore]

HK....

"Whatever the R-IT patent not a word of it will matter, because the generics will rely on 12 week renewable generic script subsitution at the pharmacy level by pharmacists/level 1 Tier shenanigans to back door steal the indication.... No one on this board has come up with a cogent reason why this will not happen if the generics win...
HK"

Guess you do not read my posts...You should. "Back door my ass.." generics are not even going to be able to get first crack at the Marine label..Unless the generics can figure out a way produce Gen V at a lower cost than Gen Lovaza. (ie Teva's drug)..It's all about the cheapest and right now Gen V and Gen L have identical labels so that 12 week renewable generic script substitution is going mean Gen V is going to be converted to cheaper Gen L..The generics have no pathway to the R-I indication and if they attempt to market the drug as a cardiac drug they will be infringing on Amarin's patents...I am predicting the generics (R & H) both settle..

Next year..The drug plans are going to have the R-I indication (it was only OKed by the FDA in late Dec. after the medicare renewal period)..At that point Amarin needs to change the label name to Vascepa Cardiac..Reflecting that Amarin alone has the right to sell this drug for the R-I indication..Please remember not every judge is going to be judge DU....

":>) JL